U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218653) titled 'Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX' on Oct. 16.
Brief Summary: This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Metabolic Syndrome
Intervention:
DRUG: Indomethacin
Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signalin...